Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans

• Published in: Journal of pharmacokinetics and pharmacodynamics Vol. 40; no. 2; pp. 157 - 176
• Main Authors: Hudachek, Susan F., Gustafson, Daniel L.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.04.2013; Springer Nature B.V
• Subjects: Administration, Oral; Animals; Antineoplastic Agents - pharmacokinetics; Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Female; Humans; Liver - metabolism; Mice; Models, Biological; Neoplasms - drug therapy; Neoplasms - metabolism; Original Paper; Pharmacology/Toxicology; Pharmacy; Quinazolines - pharmacokinetics; Quinazolines - pharmacology; Tissue Distribution - physiology; Veterinary Medicine/Veterinary Science; Breast cancer; Lapatinib; Physiologically based pharmacokinetic modeling; Tyrosine kinase inhibitor

Lapatinib is an oral 4-anilinoquinazoline derivative that dually inhibits epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2). This drug is a mere decade old and has only been approved by the FDA for the treatment of breast cancer since 2007. Consequently, the intric...